PARIS and CAMBRIDGE, Mass., Jan. 29, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO -- NASDAQ: NBTX - the ''Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in fireside chats at following conferences:

Guggenheim SMID Cap Biotech Conference

Date: Thursday, February 6, 2025

Time: 1pm ET / 7pm CET

Location: New York, NY

Get the latest news
delivered to your inbox
Sign up for The Manila Times newsletters
By signing up with an email address, I acknowledge that I have read and agree to the Terms of Service and Privacy Policy.

Presenter: Bart van Rhijn, Chief Financial & Business Officer of Nanobiotix

Webcast link: Click here

Leerink Global Healthcare Conference

Date: Wednesday, March 12, 2025

Time: 10:40pm ET / 4:40pm CET

Location: Miami, FL

Presenters: Laurent Levy, Chief Executive Officer of Nanobiotix and Bart van Rhijn, Chief Financial & Business Officer of Nanobiotix

Webcast link: Click here

The fireside chats will be webcast live from the events page of the Investors section of the Company's website. Replay of the webcast will be available following the event.

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company's philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.

Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.

Contacts

Nanobiotix 
Communications Department

Brandon Owens

VP, Communications

+1 (617) 852-4835

[email protected]

Investor Relations Department

Craig West

SVP, Investor Relations

+1 (617) 583-0211

[email protected]

 
  
Media Relations 

France - HARDY

Caroline Hardy

+33 06 70 33 49 50

[email protected]

  

Global - LifeSci Advisors

Kevin Gardner

+1 (617) 283-2856

[email protected]

 
 

Attachments